In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Nous Research has released Hermes Mixture of Agents 2.0 (MoA 2.0), an update to its open-source Hermes Agent framework that ...

Today, the industry has edged closer to production. But the biggest challenge to widespread deployment is no longer ...